重组人血管内皮抑素静脉泵入联合TP方案治疗晚期卵巢癌的临床观察及疗效评价

Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer.

作者信息

Zhang Chi, Deng Wen-Ying, Li Ning, Luo Su-Xia

机构信息

Department of Internal Medicine-Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, China.

出版信息

Chronic Dis Transl Med. 2015 Oct 9;1(3):158-162. doi: 10.1016/j.cdtm.2015.08.003. eCollection 2015 Sep.

DOI:10.1016/j.cdtm.2015.08.003

PMID:29063002

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5643571/

Abstract

OBJECTIVES

To observe the curative effects and adverse reactions of recombinant human (rh)-endostatin injection combined with a TP regimen for treating patients with advanced ovarian cancer.

METHODS

Fifty-four patients with pathologically confirmed ovarian cancer were randomly divided into a combined treatment (intravenous pump of rh-endostatin + TP regimen) group and a control (single chemotherapy) group, twenty-seven patients in each group. All patients were given a conventional CT examination. The level of vascular endothelial growth factor (VEGF), the size of tumor before treatment, after 2 cycles and after 4 cycles of treatment were determined for the comparison of curative effects and adverse reactions.

RESULTS

The effective rate was 37.0% (10/27) and disease control rate was 63.0% (17/27) in the combined treatment group after 2 cycles of treatment. The effective rate was 25.9% (7/27) and disease control rate was 63.0% (17/27) in the control group. The comparison between these two groups showed no significant differences ( > 0.05). The effective rate was 63.0% (17/27) and disease control rate was 92.6% (25/27) in the combined treatment group after 4 cycles of treatment. The effective rate was 29.6% (8/27) and disease control rate was 63.0% (17/27) in the control group. The effective rate and disease control rate between these two groups after 4 cycles of treatment showed significant differences ( < 0.05). The incidences of cardiovascular toxicity, myelosuppression, sore muscles and joints, alopecia and gastrointestinal reaction was not significantly different between two groups ( > 0.05).

CONCLUSION

The pump delivery of rh-endostatin can down-regulate the expression of VEGF in ovarian cancer and has the better curative effect and slighter adverse reactions.

摘要

目的

观察重组人（rh）-内皮抑素注射液联合TP方案治疗晚期卵巢癌患者的疗效及不良反应。

方法

54例经病理确诊的卵巢癌患者随机分为联合治疗组（rh-内皮抑素静脉泵入+TP方案）和对照组（单纯化疗组），每组27例。所有患者均行常规CT检查。测定治疗前、治疗2周期后及4周期后血管内皮生长因子（VEGF）水平、肿瘤大小，比较疗效及不良反应。

结果

联合治疗组治疗2周期后有效率为37.0%（10/27），疾病控制率为63.0%（17/27）；对照组有效率为25.9%（7/27），疾病控制率为63.0%（17/27）。两组比较差异无统计学意义（P>0.05）。联合治疗组治疗4周期后有效率为63.0%（17/27），疾病控制率为92.6%（25/27）；对照组有效率为29.6%（8/27），疾病控制率为63.0%（17/27）。治疗4周期后两组有效率及疾病控制率比较差异有统计学意义（P<0.05）。两组心血管毒性、骨髓抑制、肌肉关节酸痛、脱发及胃肠道反应发生率比较差异无统计学意义（P>0.05）。